A cytotoxic electronegative LDL subfraction is present in human plasma.
By using fast protein liquid chromatography, we isolated from human plasma a minor electronegative LDL subfraction designated LDL(-). After immunoaffinity chromatography against apolipoprotein (apo)(a) and apo A-I, LDL(-) represented 6.7 +/- 0.9% (mean +/- SD; n = 18) of total LDL. Compared with the major LDL subfraction, designated LDL(+), LDL(-) contained similar amounts of thiobarbituric acid-reactive substances, conjugated dienes, and vitamin E and had a similar lipid/protein ratio and mean density. Moreover, the apo B of LDL(-) was not aggregated and its LDL receptor-binding activity was slightly increased. These results were consistent with the nonoxidized nature of LDL(-). LDL(-) showed increased contents of sialic acid (38.1 +/- 5.2 versus 28.9 +/- 3.3 nmol/mg protein; n = 7; P < .01), apo C-III (1.43 +/- 0.21% versus 0.14 +/- 0.04%; n = 7; P < .01), and apo E (1.64 +/- 0.26% versus 0.10 +/- 0.05%; n = 7; P < .0005). Compared with LDL(+), LDL(-) displayed enhanced cytotoxic effects on cultured human umbilical vein endothelial cells, as shown by lactate dehydrogenase assay (P < .003; n = 6), neutral red uptake (P < .02; n = 6), and morphological studies. We also studied the relationship of LDL(-) to age and plasma lipid levels in 133 subjects. The percentage of contribution of LDL(-) to total plasma LDL correlated with age (P < .05), total cholesterol (P < .05), and LDL cholesterol (P < .003). In conclusion, this study shows that LDL(-), a circulating human plasma LDL, is an electronegative native LDL subfraction with cytotoxic effects on endothelial cells. This subfraction, which correlates positively with common atherosclerotic risk factors, might induce atherogenesis by actively contributing to alteration of the vascular endothelium.
Demuth
K
K
Laboratoire de Biochimie, Hôpital Broussais, Paris, France.
Myara
I
I
Chappey
B
B
Vedie
B
B
Pech-Amsellem
M A
MA
Haberland
M E
ME
Moatti
N
N
D000328:Adult; D000375:Aging / Q000097:blood; D016632:Apolipoprotein A-I / Q000276:immunology; D001054:Apolipoproteins A / Q000276:immunology; D001161:Arteriosclerosis / Q000097:blood / Q000453:epidemiology; D001797:Blood Protein Electrophoresis; D002478:Cells, Cultured; D002846:Chromatography, Affinity; D002852:Chromatography, Ion Exchange; D004730:Endothelium, Vascular / Q000187:drug effects; D005260:Female; D006801:Humans; D007163:Immunosorbent Techniques; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D015227:Lipid Peroxidation; D008055:Lipids / Q000032:analysis; D008077:Lipoproteins, LDL / Q000097:blood / Q000145:classification* / Q000302:isolation & purification / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D014470:Umbilical Cord; D014810:Vitamin E / Q000032:analysis
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D008055:Lipids; D008077:Lipoproteins, LDL; D017392:Thiobarbituric Acid Reactive Substances; D014810:Vitamin E; D007770:L-Lactate Dehydrogenase